Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature

BACKGROUND: Sunitinib and pazopanib are both oral small molecule multityrosine kinase inhibitors (MTKI) used in the treatment of renal cell carcinoma (RCC). Hepatotoxicity or “liver injury” is the most important adverse effect of pazopanib administration, but little is known about the underlying mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Studentova, Hana, Volakova, Jindriska, Spisarova, Martina, Zemankova, Anezka, Aiglova, Kvetoslava, Szotkowski, Tomas, Melichar, Bohuslav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818210/
https://www.ncbi.nlm.nih.gov/pubmed/35123392
http://dx.doi.org/10.1186/s12876-022-02121-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818210/
https://www.ncbi.nlm.nih.gov/pubmed/35123392
http://dx.doi.org/10.1186/s12876-022-02121-3

Ejemplares similares